Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action
Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...
Anavex Life Sciences (AVXL) lost ~18% in the premarket on Wednesday after the company announced that it withdrew the marketing authorization application for its Alzheimer’s candidate, blarcamesine, in ...
Anavex Life Sciences Corp. has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX®2-73), a novel oral treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results